Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Recursion Pharmaceuticals Q3 EPS $(0.36) Misses $(0.31) Estimate, Sales $5.175M Miss $16.983M Estimate

Author: Benzinga Newsdesk | November 05, 2025 06:35am
Recursion Pharmaceuticals (NASDAQ:RXRX) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.31) by 16.88 percent. This is a 5.88 percent decrease over losses of $(0.34) per share from the same period last year. The company reported quarterly sales of $5.175 million which missed the analyst consensus estimate of $16.983 million by 69.53 percent. This is a 80.16 percent decrease over sales of $26.082 million the same period last year.

Posted In: RXRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist